Iter-4360dd15-0113-transcript

修改：20260424215108000

第 113 轮执行轨迹

→ call search_memory({"limit":10,"query":"4360dd15 BOLERO-2 PMID 22149876 primary endpoint trial design accessible authority"})

【tool:search_memory】 {"ok": true, "results": [{"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹

→ call search_memory({\"limit\":10,\"query\":\"4360dd15 38310895 NEXT_FOCUS 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":10}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹

   → call search_m"}, {"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹

→ call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin review 2024 trial endpoint remaining 11\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0007-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424174944000\", \"preview\": \"!! 第 7 轮执行轨迹

   → cal"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹

→ call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":8,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"resul

→ call read_note({"title":"NEXT_FOCUS"})

→ call list_recent({"n":6})

→ call list_tools({})

【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0112）\n\n为 PMID 22149876 再补一条与 NEJM 无关、且能直接显示 trial design 和 primary endpoint 的可访问权威来源。"}

【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0112-reflection", "modified": "20260424214838000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424214838000", "tags": "pinned focus"}, {"title": "先用可访问二源闭环再碰受限原文", "modified": "20260424214838000", "tags": "lesson evidence-chain trial-screening metadata-first"}, {"title": "Iter-4360dd15-0112-transcript", "modified": "20260424214832000", "tags": "iteration transcript"}, {"title": "BOLERO-2 PMID 22149876 的第二独立复核来源与 primary endpoint", "modified": "20260424214827000", "tags": "fact knowledge 4360dd15 clinical-trials evidence-chain"}, {"title": "Error-20260425-054541", "modified": "20260424214541000", "tags": "error iteration"}]}

【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，斜体，其它tiddler。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio

→ call web_search({"limit":8,"query":"BOLERO-2 trial design primary endpoint investigator-assessed PFS accessible authority non NEJM"})

→ call pubmed_search({"limit":10,"query":"BOLERO-2 everolimus exemestane primary endpoint PFS trial design"})

→ call web_search({"limit":8,"query":"PMID 22149876 BOLERO-2 clinicaltrials.gov primary endpoint PFS"})

【tool:web_search】
{"ok": true, "query": "BOLERO-2 trial design primary endpoint investigator-assessed PFS accessible authority non NEJM", "results": [{"title": "Study Details | NCT00863655 | Everolimus in Combination With Exemestane ...", "url": "https://clinicaltrials.gov/study/NCT00863655", "snippet": "There are no treatments specifically approved after recurrence or progression on a non steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + placebo in postmenopausal women ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/pdf", "snippet": "Patients and methods: BOLERO-2 is a phase III, double-blind, randomized international trial comparing EVE 10 mg/ day plus EXE 25 mg/day versus placebo (PBO) + EXE 25 mg/day in postmenopausal women with HR+ advanced breast cancer with prior exposure to NSAIs. The primary end point was PFS by local investigator assessment; OS was a key secondary end point."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The primary end point was PFS as assessed by local investigator (per RECIST 1.0) [9]; OS was a key secondary end point. Safet

【tool:pubmed_search】
{"ok": true, "query": "BOLERO-2 everolimus exemestane primary endpoint PFS trial design", "results": []}

【tool:web_search】
{"ok": true, "query": "PMID 22149876 BOLERO-2 clinicaltrials.gov primary endpoint PFS", "results": [{"title": "Study Details | NCT00863655 - ClinicalTrials.gov", "url": "https://clinicaltrials.gov/study/NCT00863655", "snippet": "The U.S. government does not review or approve the safety and science of all studies listed on this website. Read our full disclaimer for details."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "(Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.) Endocrine therapy is the cornerstone of treatment for patients with hormone-receptor (HR)-positive advanced breast cancer."}, {"title": "Everolimus in postmenopausal hormone-receptor-positive ... - Europe PMC", "url": "https://europepmc.org/abstract/MED/22149876", "snippet": "Conclusions Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.)."}, {"title": "Everolimus plus exemestane as first-line therapy in HR +, HER2 − ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3907668/", "snippet": "The primary endpoint of BOLERO-2 was investigator-assessed PFS (defined as time from randomization to first documented progression or death from any cause) per Re

→ call web_fetch({"max_chars":5000,"url":"https://clinicaltrials.gov/study/NCT00863655"})

→ call web_fetch({"max_chars":5000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3907668/"})

→ call web_fetch({"max_chars":4000,"url":"https://europepmc.org/abstract/MED/22149876"})

【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://clinicaltrials.gov/study/NCT00863655'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}

【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3907668/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.", "truncated": false}

【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/22149876", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}

→ call web_search({"limit":10,"query":"site:europepmc.org 22149876 abstract BOLERO-2 investigator-assessed PFS RECIST"})

→ call web_search({"limit":10,"query":"site:ascopubs.org BOLERO-2 primary end point PFS local investigator review"})

→ call web_search({"limit":10,"query":"site:clinicaltrials.gov NCT00863655 phase III double-blind randomized BOLERO-2 primary endpoint"})

【tool:web_search】
{"ok": true, "query": "site:europepmc.org 22149876 abstract BOLERO-2 investigator-assessed PFS RECIST", "results": [{"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://europepmc.org/articles/PMC6267855", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival ( PFS ) by more than twofold in patients with hormone-receptor-positive (HR (+)), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase ..."}, {"title": "The BOLERO-2 trial: the addition of everolimus to exemestane in the ...", "url": "https://europepmc.org/article/MED/22764762", "snippet": "Abstract The combination of the mTOR inhibitor everolimus with the aromatase inhibitor exemestane was evaluated in the randomized Phase III BOLERO-2 trial. Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies."}, {"title": "Using quality-adjusted progression-free survival as an outcome measure ...", "url": "https://europepmc.org/articles/PMC4461432", "snippet": "Our analysis was based on local PFS assessment, which happened to be the primary endpoint of the BOLERO-2 trial. Efficacy of anti-cancer drugs is assessed locally in routine clinical practice."}, {"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/a

【tool:web_search】
{"ok": true, "query": "site:ascopubs.org BOLERO-2 primary end point PFS local investigator review", "results": [{"title": "BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane ...", "url": "https://ascopubs.org/doi/10.1200/jco.2013.31.26_suppl.152", "snippet": "Methods: BOLERO-2 enrolled patients with hormone receptor-positive (HR+) advanced breast cancer with disease recurrence or progression after prior nonsteroidal aromatase inhibitors and compared EVE (10 mg/d) + EXE (25 mg/d) vs PBO + EXE. The primary end point was PFS by local investigator review ."}, {"title": "Everolimus for postmenopausal women with advanced breast cancer ...", "url": "https://ascopubs.org/doi/10.1200/jco.2012.30.15_suppl.559", "snippet": "The primary endpoint was PFS by local investigator assessment. Main secondary endpoints included centrally assessed PFS , overall survival (OS), safety, bone turnover, and overall response rate (ORR). Results: Baseline disease characteristics including tumor burden and prior cancer therapy were well balanced between treatment arms (N = 724)."}, {"title": "Everolimus plus exemestane in patients with advanced invasive lobular ...", "url": "https://ascopubs.org/doi/10.1200/jco.2014.32.26_suppl.152", "snippet": "Methods: Pts with HR+, HER2- ABC recurring or progressing on/after prior nonsteroidal aromatase inhibitor therapy were randomized 2:1 to receive EVE 10 mg/day + EXE 25 mg/day or PBO + EXE. Primary efficacy end point was PFS (by local assessmen

【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov NCT00863655 phase III double-blind randomized BOLERO-2 primary endpoint", "results": []}

→ call web_fetch({"max_chars":5000,"url":"https://europepmc.org/article/MED/22149876"})

→ call web_fetch({"max_chars":6000,"url":"https://ascopubs.org/doi/10.1200/jco.2012.30.15_suppl.559"})

【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://ascopubs.org/doi/10.1200/jco.2012.30.15_suppl.559'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}

→ call web_search({"limit":5,"query":"\"PMC3898123\" BOLERO-2 phase 3 double-blind randomized international trial primary endpoint PFS by local investigator review"})

【tool:web_search】
{"ok": true, "query": "\"PMC3898123\" BOLERO-2 phase 3 double-blind randomized international trial primary endpoint PFS by local investigator review", "results": []}

→ call web_search({"limit":10,"query":"NCI BOLERO-2 phase III trial primary endpoint progression-free survival everolimus exemestane"})

→ call web_search({"limit":10,"query":"FDA BOLERO-2 primary endpoint PFS everolimus exemestane summary"})

→ call web_search({"limit":10,"query":"BOLERO-2 trial design primary endpoint accessible review everolimus exemestane site:nih.gov"})

【tool:web_search】
{"ok": true, "query": "NCI BOLERO-2 phase III trial primary endpoint progression-free survival everolimus exemestane", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival , with observed medians of 6.9 and 2.8 months, corresponding to a 57% ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR+), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal arom

【tool:web_search】
{"ok": true, "query": "FDA BOLERO-2 primary endpoint PFS everolimus exemestane summary", "results": [{"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival ( PFS ) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analysis is ..."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival, with observed medians of 6.9 and 2.8 months, corresponding to a 57% ..."}, {"title": "Everolimus in Combination With Exemestane in the Treatment of ...", "url": "https://clinicaltrials.gov/study/NCT00863655", "snippet": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole ( BOLERO-2 )"}, {"title": "CTR RAD001Y2301_Final_24Nov2015 - novctrd.com", "url": "https://www.novctrd.com/ctr

【tool:web_search】
{"ok": true, "query": "BOLERO-2 trial design primary endpoint accessible review everolimus exemestane site:nih.gov", "results": [{"title": "Everolimus plus exemestane as first-line therapy in HR +, HER2 − ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3907668/", "snippet": "The mTOR inhibitor everolimus (EVE) in combination with exemestane (EXE) was recently approved for the treatment of postmenopausal women with HR +, HER2 − advanced breast cancer whose disease recurred or progressed during or after nonsteroidal AI (NSAI) therapy [11]. This approval was based on the results of the pivotal BOLERO-2 trial , wherein EVE + EXE more than doubled median progression ..."}, {"title": "Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4372651/", "snippet": "The BOLERO-2 study was an international, double-blind, randomized, phase III study comparing everolimus plus exemestane to placebo plus exemestane in postmenopausal women with hormone receptor-positive/HER2 − advanced breast cancer progressing during or following nonsteroidal aromatase inhibitor therapy with either letrozole or anastrozole ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more

→ call web_search({"limit":5,"query":"escholarship BOLERO-2 primary endpoint investigator assessed PFS trial design"})

【tool:web_search】
{"ok": true, "query": "escholarship BOLERO-2 primary endpoint investigator assessed PFS trial design", "results": [{"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "BOLERO-2 is a phase III, double-blind, randomized international trial comparing EVE 10 mg/day plus EXE 25 mg/day versus placebo (PBO) + EXE 25 mg/day in postmenopausal women with HR + advanced breast cancer with prior exposure to NSAIs. The primary end point was PFS by local investigator assessment; OS was a key secondary end point."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "The trial met its primary end point, progression-free survival; the median progression-free survival, on the basis of radiographic studies assessed by the local investigators , was 6.9 months for ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The primary end point was PFS as assessed by local investigator (per RECIST 1.0) [9]; OS was a key secondary end point. Safety assessments are described in the supplementary materials, available at Annals of Oncology online. Poststudy anticancer therapies were recorded for at least the first treatment after discontinuation."}, {"title": "Everolimus Plu

→ call web_fetch({"max_chars":7000,"url":"https://escholarship.org/uc/item/0715f3jd"})

【tool:web_fetch】
{"ok": true, "url": "https://escholarship.org/uc/item/0715f3jd", "status": 202, "content_type": "text/html; charset=UTF-8", "text": "", "truncated": false}

→ call search_memory({"limit":5,"query":"4360dd15 BOLERO-2 PMID 22149876 primary endpoint PFS fact knowledge"})

【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹

   → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"})    → call list_recent({\"n\":10})    → call list_tools({})  【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹

→"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹

   → call search_memory({\"limit\":10,\"query\":\"4360dd15 38310895 NEXT_FOCUS 原始人类试验 PMID 主要终点\"})    → call list_recent({\"n\":10})    → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"})  【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹

→ call search_m"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹

   → call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 原始人类试验 PMID 主要终点\"})    → call list_recent({\"n\":8})    → call list_by_tag({\"limit\":8,\"tag\":\"4360dd15\"})  【tool:search_memory】 {\"ok\": true, \"results\": 
  → call web_fetch({"max_chars":6000,"url":"https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6843"})
  → call web_search({"limit":5,"query":"\"trial met its primary PFS endpoint\" BOLERO-2 PDF"})
  → call web_search({"limit":5,"query":"\"BOLERO-2\" \"phase 3, double-blind, randomized, international trial\" primary endpoint PFS"})【tool:web_fetch】
{"ok": true, "url": "https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6843", "status": 200, "content_type": "application/pdf", "text": "%PDF-1.6\r%��